Recombinant avian herpesviruses containing multiple foreign genes

By inserting recombinant nucleotide sequences into specific intergenic regions of the herpesvirus genome, stable, multivalent viruses are created that effectively express multiple antigens, addressing instability issues and providing robust immunity against avian diseases.

JP7590329B2Active Publication Date: 2024-11-26セヴァサンテアニマレ
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021535921
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-21
Filing Date
2019-12-20
Publication Date
2024-11-26
Estimated Expiration
2039-12-20

AI Technical Summary

Technical Problem

Existing recombinant herpesviruses used for poultry vaccination often face instability and inadequate expression of multiple foreign genes, leading to interference and immunosuppression, necessitating the development of stable, multivalent viruses that can express multiple antigens effectively.

Method used

Recombinant avian herpesviruses are engineered with multiple recombinant nucleotide sequences inserted into specific intergenic regions of the viral genome, specifically between HVT053 and HVT054, and between HVT064 and HVT070, to ensure stable expression of antigens like NDV-F and ILTV-gB, using promoters such as Pec and Mcmv ie1 to enhance gene expression.

Benefits of technology

The engineered viruses demonstrate high stability and strong, long-term expression of multiple antigens, inducing robust protective immunity against avian pathogens, with up to 80% protection after three weeks of vaccination.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590329000010
    Figure 0007590329000010
  • Figure 0007590329000011
    Figure 0007590329000011
  • Figure 0007590329000012
    Figure 0007590329000012
Patent Text Reader

Abstract

The present invention relates to recombinant avian herpesviruses containing multiple genes inserted into separate intergenic regions, their production, compositions containing same, and their uses.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to recombinant herpesviruses having at least two recombinant nucleotide sequences inserted therein, and uses thereof. The present invention is particularly suitable for producing multivalent viruses or compositions, such as vaccines, capable of inducing protective immunity against avian pathogens or diseases. [Background technology]

[0002] Poultry meat and eggs are important food sources, and their consumption is constantly increasing due to the growing population and its excellent quality-price ratio. To ensure poultry health as well as food safety and security, poultry vaccine technology has become a global concern.

[0003] Viral vectors expressing pathogen proteins are commonly used as poultry vaccines against target pathogens. Vaccines containing such viral vectors induce the expression of foreign pathogen proteins in the infected host, which can lead to protective immunity.

[0004] Many different classes of viruses have been investigated as candidate vectors for avian vaccination, including adenoviruses, AAV, fowlpox viruses, and herpes viruses.

[0005] Three herpesviruses have been identified: MDV1, MDV2, and MDV3 (also known as herpesvirus of turkeys (HVT)). There is a high degree of similarity between these viruses (see Kingham et al., Journal of General Virology (2001) 82, 1123-1135), and they have all been used to prepare recombinant viruses incorporating foreign genes derived from pathogens for use as vaccines in birds, particularly poultry such as chickens.

[0006] Although such vaccine preparations provide efficient results for vaccinating avian species against many diseases, inter-pathogen competition and immunosuppression can occur when birds are injected with two or more recombinant herpesviruses, each encoding a different antigen.

[0007] To overcome such interference and also to facilitate vaccination against multiple diseases, various attempts have been made to generate polyvalent herpesviruses encoding several antigens.

[0008] In initial studies, several genes were inserted into a single cloning site in the genome of a herpesvirus (see, for example, EP 1026246), but such constructs either did not confer the required level of protective immunity or proved unstable, resulting in the deletion of all or part of the foreign genes during repeated passaging in cultured cells.

[0009] WO2013 / 144355 reports stable herpes viruses encoding multiple foreign antigens obtained using a combination of cloning sites located in non-coding regions of the viral genome.

[0010] WO2013 / 057236, WO2013 / 082327 and WO2013 / 082317 report another approach in designing a multivalent HVT by cloning at least one gene into the US2 coding sequence of a herpesvirus. According to these applications, US2 is not essential for viral replication, but such a property has not been verified.

[0011] Given the number of pathogens and species, there is a need in the art for additional recombinant polyvalent herpesviruses that are capable of stably expressing multiple genes in vivo and are suitable for vaccination of birds, particularly poultry. Summary of the Invention

[0012] The present invention provides recombinant avian herpesviruses that contain multiple recombinant nucleotide sequences in at least two distinct locations in the viral genome.

[0013] More specifically, the present invention provides a recombinant herpesvirus of turkeys (HVT) comprising at least a first and a second recombinant nucleotide sequence, each of which encodes a polypeptide, the first recombinant nucleotide sequence being inserted into an intergenic region of the viral genome located between HVT053 (UL45) and HVT054 (UL46), and the second recombinant nucleotide sequence being inserted into an intergenic region of the viral genome located between HVT064 (LORF3) and HVT070, particularly HVT070. It is inserted into the intergenic region of the viral genome located between HVT064(LORF3) and HVT065(UL55), between HVT065(UL55) and HVT066(LORF4), between HVT066(LORF4) and HVT067(LORF5), between HVT067(LORF5) and HVT069(LORF6), or between HVT069(LORF6) and HVT070, and more specifically between HVT065(UL55) and HVT066(LORF4).

[0014] Each recombinant nucleotide may code for the same or different polypeptides, particularly antigens, cytokines, adjuvants, hormones, etc. In certain embodiments, each recombinant nucleotide codes for antigens, which may be the same or different (or the same or different parts of the same antigen), and may be derived from the same pathogen or different pathogens. Antigens may be selected or derived, for example, from surface, secreted, or structural proteins of the pathogen, or immunogenic fragments thereof.

[0015] The present invention also relates to a nucleic acid comprising the genome of a recombinant HVT as defined above, and to a vector (such as a plasmid) comprising such a nucleic acid.

[0016] The present invention further relates to a cell containing a recombinant HVT or a nucleic acid or a vector as defined above.

[0017] A further object of the present invention is a composition comprising a recombinant HVT as defined above and a suitable excipient or diluent.

[0018] A further object of the present invention is a composition comprising a nucleic acid or a cell as defined above and a suitable excipient or diluent.

[0019] Another object of the invention is a vaccine comprising an effective immunizing amount of a recombinant HVT, nucleic acid and / or cells as defined above.

[0020] A further object of the present invention resides in a recombinant HVT, nucleic acid or cell as defined above for use in immunizing birds, such as poultry, against pathogens.

[0021] A further object of the present invention resides in a recombinant HVT, nucleic acid or cell as defined above for use in protecting birds, such as poultry, against diseases caused by pathogens.

[0022] A further object of the invention resides in a vaccine as defined above for use in vaccinating birds, such as poultry, against one or more pathogens.

[0023] A further object of the present invention is a method for vaccinating a bird, comprising administering to said bird a composition or a vaccine or a virus as defined above.

[0024] A further object of the present invention is a method for inducing an immune response in a bird against an antigen, comprising administering to the bird a composition or a vaccine or a virus as defined above.

[0025] The present invention also relates to a method for producing a composition comprising the following components: a. an effective amount of a composition or vaccine as defined above, and b. a means for administering said composition or vaccine to said bird.

[0026] The present invention may be used in any bird for vaccination against any avian pathogen, and is particularly suited for vaccination of poultry, such as chickens. [Brief description of the drawings]

[0027] [Figure 1A] A schematic diagram of the HVT genome is shown. The locations of unique long (UL) 45 (HVT053) and UL46 (HVT054) and the locations of unique longs HVT064-070 are marked. Recombinant nucleotide sequences can be inserted into the PCR-generated SfiI sites between HVT053 (UL45) and HVT054 (UL46), and between HVT064 and 065, and / or between HVT065 and 066, and / or between HVT066 and 067, and / or between HVT067 and 069, and / or between HVT069 and 070. [Figure 1B] Also depicted are HVT constructs incorporating different clusters of nucleotide sequences and promoters according to certain embodiments of the invention. [Diagram 2]Figure 2A shows immunofluorescence staining of CEF infected with double recombinant HVT by the embodiment of the present invention (FW241 and FW242) co-expressing NDV-F and ILTV-gB (rHVT / ND / ILT infected cells). The expression of protein F was detected by anti-F Mab (77-2) and Alexa Flour 488. The expression of protein gB was detected by anti-gBN4 rabbit serum and Alexa Flour 546. The results show that both cells infected with FW241 or FW242 express both inserted NDV-F protein and inserted ILTV-gB protein. They were observed by fluorescence microscope at 40 times magnification. Figure 2B shows immunofluorescence staining of CEF infected with double recombinant HVT by the embodiment of the present invention (FW259) co-expressing IBDV VP2 and ILTV-gB (rHVT / IBD / ILT infected cells). The expression of protein VP2 was detected by anti-VP2 Mab (R63) and Alexa Flour 488. The expression of protein gB was detected by anti-gBN4 rabbit serum and Alexa Flour 546. The results show that cells infected with FW259 express both the inserted IBDV-VP2 protein and the inserted ILTV-gB protein. They were observed under a fluorescent microscope at 100x magnification. [Figure 3A-3B] 3 is a Western blotting analysis showing the expression of F protein and / or gB protein in CEF infected with the rHVT of the present invention. As shown in FIG. 3A, a 60 kilodalton (kDa) protein band was observed only in one lane of rHVT / ND / ILT-infected cells, which is the expected size of the F protein.

number

number

[0028] The present invention relates generally to recombinant avian herpesviruses comprising multiple recombinant nucleotide sequences, their production, compositions comprising same, and uses thereof.

[0029] definition This disclosure will be best understood by reference to the following definitions. The term "recombinant" with respect to herpesvirus refers to a herpesvirus that has been modified by the insertion of at least one nucleotide sequence (e.g., DNA, such as a gene) that is not naturally found in the genome of the herpesvirus, or that is naturally found in the genome but in a different form or location. It will be understood that recombinant herpesviruses can be produced by a variety of methods, such as the recombinant DNA techniques described therein, and that once produced, they can be replicated without the further use of recombinant DNA techniques. Thus, the structure of a "recombinant herpesvirus" is described in terms of DNA insertion.

[0030] As used herein, the terms "nucleic acid," "nucleic acid sequence," and "nucleotide sequence" are used interchangeably and refer to a nucleic acid molecule having a determined sequence, which may be deoxyribonucleotides and / or ribonucleotides. A nucleotide sequence may be initially prepared, for example, by recombinant, enzymatic, and / or chemical techniques, and subsequently replicated in a host cell or in vitro system. A nucleotide sequence preferentially includes a translation region that codes for a molecule (e.g., a peptide or protein). A nucleotide sequence may include additional sequences such as a promoter, transcription terminator, signal peptide, IRES, etc. Preferably, the translation region of a recombinant nucleic acid does not include introns.

[0031] A "recombinant nucleotide sequence" refers to a sequence that is not naturally found in the genome of a herpesvirus, or a sequence that is naturally found in the genome, but in a different form or location. A typical "recombinant nucleotide sequence" is preferably a gene that encodes a molecule that is not naturally produced by an avian herpesvirus, such as a molecule from a different virus or cell. A "gene" in the context of such a "recombinant nucleotide sequence" refers to any nucleic acid molecule that includes a translation region, such as a nucleic acid that consists of or consists essentially of a translation region. A gene may further include regulatory elements, such as, for example, a promoter or a terminator.

[0032] As used herein, the terms "polypeptide," "peptide," and "protein" are used interchangeably and refer to any molecule comprising a polymer of at least two consecutive amino acids.

[0033] The term "intergenic region" is well known in the art and refers to any region of a viral genome located between two specific viral ORFs. Thus, the intergenic region between UL45 (HVT053) and UL46 (HVT054) refers to the region that begins immediately 3' of the stop codon of UL45 and ends immediately 5' of the stop codon of UL46 (since both ORFs are in opposite orientations). The intergenic region between HVT064 and HVT065 refers to the region that begins immediately 3' of the start codon of HVT064 and ends immediately 5' of the start codon of HVT065 (since both ORFs are in opposite orientations). Similarly, the intergenic region between HVT065 and HVT066 refers to the region that begins immediately 3' of the stop codon of HVT065 and ends immediately 5' of the stop codon of HVT066 (since both ORFs are in opposite orientations). An intergenic region may include a regulatory region such as a terminator or promoter.

[0034] The term "avian species" is intended to encompass all types of birds, including birds of the class Aves, i.e., feathered, winged, bipedal, endothermic and egg-laying vertebrates. In the context of the present invention, birds or avian species more specifically refer to birds of economic and / or agricultural interest, such as poultry (such as chickens and turkeys), waterfowl (such as ducks and geese) and ornamental birds (e.g., swans and parrots).

[0035] As used herein, the term "vaccine" refers to an agent that can be used to induce, stimulate, or amplify an immune response in an organism.

[0036] The term "multivalent" as used herein in connection with a recombinant herpesvirus, vector, or vaccine of the present invention refers to a recombinant herpesvirus or vaccine comprising at least two recombinant nucleotide sequences as defined above, which sequences are the same or different and derived from the same or different pathogens.

[0037] Multivalent recombinant HVT The present invention relates to a recombinant HVT containing multiple foreign genes at specific locations. More specifically, the present invention shows that a stable and effective multivalent recombinant HVT can be obtained in the following cases: at least one recombinant nucleotide sequence is cloned into an intergenic region of the genome located between HVT053 and HVT054; and At least one recombinant nucleotide sequence is cloned into an intergenic region of the genome located between HVT064 and HVT070.

[0038] As shown in the Examples, when such a combination of sites is used, the recombinant HVT is stable for at least 10, preferably at least 15, more preferably at least 20 passages in CEF cells. Furthermore, using such a combination of sites, strong and long-term expression of genes can be obtained in vivo, sufficient to obtain high protective immunity.

[0039] There are many potential cloning sites in recombinant herpesviruses. In particular, there are nearly 397 ORFs in herpesvirus genomes, 99 of which are predicted to code for functional protein products (see Afonso et al., J. Virology 75(2), 2001, 971). Furthermore, some cloning sites suitable for use in the context of monovalent viruses have shown instability when used in the context of polyvalent viruses, especially when two different cloning sites are used in the same virus. The present invention shows that the combination of the intergenic region between HVT053 and HVT054 and the intergenic region between HVT064 and HVT070 allows for stability and suitable levels of expression of both cloned recombinant nucleotide sequences in vitro. Thus, such specific recombinant viruses represent novel and effective agents for inducing strong protective immunity in vivo.

[0040] In a particular embodiment, the present invention relates to a recombinant HVT comprising a plurality of recombinant nucleic acids (e.g., foreign genes), at least one recombinant nucleic acid is cloned into an intergenic region of the genome located between HVT053 and HVT054; At least one recombinant nucleic acid is cloned into an intergenic region of the genome located between HVT064 and HVT065.

[0041] In a further specific embodiment, the present invention relates to a recombinant HVT comprising a plurality of recombinant nucleic acids (e.g., foreign genes), at least one recombinant nucleic acid is cloned into an intergenic region of the genome located between HVT053 and HVT054; At least one recombinant nucleic acid is cloned into an intergenic region of the genome located between HVT065 and HVT066.

[0042] In a further specific embodiment, the present invention relates to a recombinant HVT comprising a plurality of recombinant nucleic acids (e.g., foreign genes), at least one recombinant nucleic acid is cloned into an intergenic region of the genome located between HVT053 and HVT054; At least one recombinant nucleic acid is cloned into an intergenic region of the genome located between HVT066 and HVT067.

[0043] In another specific embodiment, the present invention relates to a recombinant HVT comprising a plurality of recombinant nucleic acids (e.g., foreign genes), at least one recombinant nucleic acid is cloned into an intergenic region of the genome located between HVT053 and HVT054; At least one recombinant nucleic acid is cloned into an intergenic region of the genome located between HVT067 and HVT069. Such an intergenic region may overlap to a limited extent with the HVT068 ORF, which is, however, located on the complementary strand. Thus, cloning into such an intergenic region may alter the HVT068 coding sequence.

[0044] In a further specific embodiment, the present invention relates to a recombinant avian HVT comprising a plurality of recombinant nucleic acids (e.g., foreign genes), at least one recombinant nucleic acid is cloned into an intergenic region of the genome located between HVT053 and HVT054; At least one recombinant nucleic acid is cloned into an intergenic region of the genome located between HVT069 and HVT070.

[0045] The recombinant HVT of the present invention can be prepared from any HVT, preferably from a non-pathogenic HVT. An example of a non-pathogenic strain of HVT (MDV3) suitable for use in the present invention is the FC126 strain.

[0046] The genome sequence of the FC126 strain is available in the art (Afonso et al., supra; Kingham et al., supra). The location of the cited intergenic regions can be easily identified by those skilled in the art using the teachings of this application, general knowledge, and sequence information available in the literature. For example, Kingham et al., supra, report the nucleotide sequence of the FC126 reference strain, as well as the location of most of the ORFs in its genome.

[0047] With reference to the FC126 complete genome (GenBank: AF291866.1), the intergenic region between HVT053 and HVT054 corresponds to nucleotides 95323 to 95443 of the HVT genome, the intergenic region between HVT064 and HVT065 corresponds to nucleotides 111304 to 111499 of the HVT genome, and the intergenic region between HVT065 and HVT066 corresponds to nucleotides 111304 to 111499 of the HVT genome. The intergenic region between HVT066 and HVT067 corresponds to nucleotides 112766 to 113107 of the HVT genome, the intergenic region between HVT067 and HVT069 corresponds to nucleotides 113906 to 114078 of the HVT genome, and the intergenic region between HVT069 and HVT070 corresponds to nucleotides 116731 ​​to 116831 of the HVT genome.

[0048] In this application, reference to the complete genome of strain FC126 is a reference to said strain as described in Genbank under accession number AF291866.1 on the filing date of this application.

[0049] The recombinant nucleotide sequence inserted into the genome can be in any orientation.

[0050] In a preferred embodiment, the recombinant HVT of the present invention comprises: at least one recombinant nucleotide sequence cloned into an intergenic region of the genome between HVT053 and HVT054; and · at least one recombinant nucleotide sequence cloned into the intergenic region of the genome between HVT065 and HVT066;

[0051] In certain embodiments, the nucleic acid inserted into the intergenic region between HVT053 and HVT054 is in the same orientation as HVT054.

[0052] In another specific embodiment, the recombinant nucleotide sequence inserted into the intergenic region between HVT065 and HVT066 is in the same orientation as HVT066.

[0053] The recombinant nucleotide sequence or the inserted nucleic acid sequence may comprise (or be operably linked to) regulatory sequences such as promoters and / or terminators. The promoters used may be either synthetic or natural, endogenous or heterologous promoters. In principle, any promoter may be used, as long as it is capable of functioning effectively in the target cell or host. In this regard, the promoter may be eukaryotic, prokaryotic, viral or synthetic promoter, and may direct gene transcription in avian cells in the context of a multivalent vector. Also, each recombinant nucleotide sequence may comprise a promoter, which may be the same or different from each other.

[0054] Preferentially, the promoter used for each recombinant nucleotide sequence is selected from the chicken beta actin (Bac) promoter, the Pec promoter, the murine cytomegalovirus (Mcmv) ie1 promoter, the human cytomegalovirus (Hcmv) promoter, the simian virus 40 (SV40) promoter, and the Rous sarcoma (RSV) promoter, or any fragment thereof that retains promoter activity.

[0055] The nucleic acid sequence of the chicken Bac promoter is shown in SEQ ID NO: 1, the sequence of the Pec promoter in SEQ ID NO: 2 and the sequence of the Mcmv ie1 promoter in SEQ ID NO: 3. It should be noted that variants of such sequences that encode functional promoters are known and / or can be designed / tested by the skilled artisan for use in the present invention.

[0056] In a preferred embodiment, the recombinant nucleotide sequence inserted into the intergenic region located between HVT053 and HVT054 comprises a Pec or Bac promoter. The results obtained by the inventors show that such promoters are efficient when placed in the cloning site in the context of the polyvalent vector of the invention.

[0057] In another preferred embodiment, the foreign gene inserted into the intergenic region located between HVT065 and HVT066 contains the Pec or Mcmvie1 promoter. The results obtained by the inventors show that such promoters are particularly efficient when placed in the cloning site in the context of the polyvalent vector of the invention.

[0058] Particularly preferred recombinant HVTs of the present invention include (i) a recombinant nucleic acid inserted into the intergenic region between HVT065 and HVT066 under the control of the Pec or Mcmv ie1 promoter, and (ii) a recombinant nucleic acid inserted into the intergenic region between HVT053 and HVT054 under the control of the Pec promoter.

[0059] Recombinant nucleotide sequences The recombinant nucleotide sequence can encode any polypeptide of interest. The recombinant nucleotide sequence can encode a polypeptide such as, for example, an antigen, a cytokine, a hormone, or an adjuvant.

[0060] In certain embodiments, one or each of the at least two recombinant nucleotide sequences encodes an antigen from a pathogen or an immunogenic fragment thereof.

[0061] They may be derived or obtained from any pathogenic organism capable of causing infection in avian species. Examples of pathogens that cause infections in birds include viruses, bacteria, fungi, and protozoa.

[0062] The antigen may be any immunogenic peptide or protein of a pathogen, such as a peptide or protein selected from or derived from a surface, secreted or structural protein, or fragments thereof, of said pathogen.

[0063] Preferred recombinant nucleotide sequences for use in the present invention encode antigens from avian influenza virus, avian paramyxovirus type 1 (also known as Newcastle disease virus (NDV)), avian metapneumovirus, Marek's disease virus, Gumboro disease virus (also known as infectious bursal disease virus (IBDV)), infectious laryngotracheitis virus (ILVT), infectious bronchitis virus (IBV), Escherichia coli, Salmonella, Pasteurella multocida, Riemerella anatipestifer, Ornithobacterium rhinotracheale, Mycoplasma gallisepticum, Mycoplasma synoviae, Mycoplasma organisms infecting avian species, and / or coccidia.

[0064] Preferentially, at least one of the recombinant nucleotide sequences inserted into the viral genome encodes an antigen selected from the F protein of NDV, the VP2 protein of IBDV, the gB protein of ILTV, the 40K protein of Mycoplasma gallisepticum, and the surface protein hemagglutinin (HA) of avian influenza virus, or an immunogenic fragment thereof. Preferentially, both recombinant nucleotide sequences, whether the same or not, encode such an antigen.

[0065] An immunogenic fragment of an antigen refers to any fragment capable of inducing an immune response to the antigen in vivo, preferably any fragment containing an epitope. An immunogenic fragment generally contains 5 to 50 consecutive amino acid residues of the antigen, for example, 5 to 40 or 10 to 40 amino acid residues.

[0066] Various combinations of antigenic peptides can be considered.

[0067] In one embodiment, the recombinant HVT of the present invention comprises a recombinant nucleotide sequence encoding the F protein or an immunogenic fragment thereof of NDV, and a nucleotide sequence encoding the VP2 protein or an immunogenic fragment thereof of IBDV.

[0068] In another embodiment, the recombinant HVT of the present invention comprises a nucleotide sequence encoding the VP2 protein or an immunogenic fragment thereof of IBDV, and a nucleotide sequence encoding the gB protein or an immunogenic fragment thereof of ILTV.

[0069] In a preferred embodiment, the recombinant HVT of the present invention comprises a nucleotide sequence encoding the F protein or an immunogenic fragment thereof of NDV, and a nucleotide sequence encoding the gB protein or an immunogenic fragment thereof of ILTV.

[0070] In another variant, the recombinant HVT of the present invention expresses two or more antigens from the same pathogen, which may be the same or different.

[0071] In further variants, at least one of the recombinant nucleotide sequences encodes an active molecule, such as a cytokine or immunomodulator, adjuvant, hormone, antiparasitic agent, antibacterial agent, etc., and the other encodes, for example, an antigen.

[0072] According to a further embodiment, three or more recombinant nucleotide sequences are inserted into the viral genome.

[0073] How to build it The recombinant HVT of the present invention can be prepared using techniques known per se in the art, such as recombinant techniques, homologous recombination, site-specific insertion, mutagenesis, and the like.

[0074] Gene cloning and plasmid construction are well known to those of skill in the art and can essentially be performed by standard molecular biology techniques (Molecular Cloning: A Laboratory Manual. 4th Edition, Cold Spring Harbor Laboratory Press, Woodbury, NY 2012).

[0075] Herpes viruses can grow in any suitable host cell and medium. Examples of the host and conditions for growing herpes viruses include chicken-derived cells such as CEF (chicken embryo fibroblasts) and chicken kidney cells. Such cells can be cultured in a medium such as Eagle's MEM or Leibowitz-L-15 / McCoy 5A (1:1 mixture) medium at about 37°C for 3 to 4 days.

[0076] Genomic DNA can be extracted from virus-infected cells according to any conventional method, in particular, after protein has been denatured and removed with a lysis buffer, DNA can be extracted with phenol and ethanol.

[0077] In general, recombinant viruses can be prepared by homologous recombination between the viral genome and a construct (e.g., a plasmid) that contains the recombinant nucleotide sequence or nucleic acid to be inserted, flanking nucleotides from the insertion site that allow recombination. Briefly, a sequence containing the target intergenic region is first cloned into a plasmid or other suitable vector. Examples of plasmids include pBR322, pBR325, pBR327, pBR328, pUC18, pUC19, pUC7, pUC8, and pUC9, examples of phages include lambda phage and M13 phage, and an example of a cosmid includes pHC79. The cloned region should preferably be of sufficient length so that upon insertion of the foreign gene, the sequences flanking the foreign gene are of appropriate length to allow in vitro homologous recombination with the viral genome. Preferably, each flanking sequence has a length of at least about 50 nucleotides.

[0078] To insert one or more recombinant nucleotide sequences into the intergenic region, a mutation can be made at a specific site in the intergenic region to create a cleavage site for a restriction enzyme. The method for making the mutation can be a conventional method, and methods commonly used by those skilled in the art, such as in vitro mutagenesis and PCR, can be used. Thus, in the PCR method, a mutation such as a deletion, substitution, or addition of 1-2 nucleotides in a PCR primer is made, and then the mutation is made using the primer. Alternatively, a naturally occurring restriction site may be used. The foreign gene (and promoter) is then inserted into the insertion site of the viral genome in the plasmid.

[0079] The obtained plasmid can be introduced into HV-infected cells or HV genome-transfected cells using any appropriate technique (e.g., electroporation, calcium phosphate, lipofectin-based methods, etc.). When the amount of plasmid to be introduced is in the range of 0.1-1000 μg, the efficiency of generating recombinant viruses by recombination between the homologous region of the HV genome and the plasmid is high in the cells. This allows recombination events between the plasmid and the viral genome to occur, and the recombinant nucleotide sequence is inserted into the virus.

[0080] The resulting recombinant viruses can be genotypically or phenotypically selected using known selection techniques, for example, by hybridization, detection of an enzymatic activity encoded by a gene co-inserted with the recombinant nucleic acid sequence, or detection of an antigenic peptide immunologically expressed by the recombinant herpesvirus.

[0081] The selected recombinant herpes virus can be grown on a large scale in cell culture. Once produced, the virus can be propagated in suitable cells.

[0082] Preferred Embodiments The following recombinant HVTs are preferred specific embodiments of the present invention. As shown in the examples, they enable a strong immune response in vivo against the antigen encoded by each recombinant nucleotide sequence.

[0083] A particularly preferred recombinant HVT of the present invention comprises (i) a recombinant nucleotide sequence encoding the F protein or an immunogenic fragment of NDV, preferentially under the control of the Mcmv ie1 promoter, inserted into the intergenic region between HVT065 and HVT066, and (ii) a recombinant nucleotide sequence encoding the gB protein or an immunogenic fragment of ILTV, preferentially under the control of the Pec promoter (FW243), inserted into the intergenic region between HVT053 and HVT054.

[0084] Another particularly preferred recombinant HVT of the present invention is a recombinant avian herpesvirus comprising: (i) a recombinant nucleotide sequence encoding the gB protein or an immunogenic fragment thereof of ILTV, preferentially under the control of the Pec promoter, inserted into the intergenic region between HVT065 and HVT066; and (ii) a recombinant nucleotide sequence encoding the F protein or an immunogenic fragment thereof of NDV, preferentially under the control of the Pec promoter (FW242), inserted into the intergenic region between HVT053 and HVT054.

[0085] Another particularly preferred recombinant HVT of the present invention is a recombinant avian herpesvirus comprising (i) a recombinant nucleotide sequence encoding the gB protein or an immunogenic fragment thereof of ILTV, preferentially under the control of the Mcmv ie1 promoter, inserted into the intergenic region between HVT065 and HVT066, and (ii) a recombinant nucleotide sequence encoding the F protein or an immunogenic fragment thereof of NDV, preferentially under the control of the Pec promoter (FW244), inserted into the intergenic region between HVT053 and HVT054.

[0086] Another particularly preferred recombinant HVT of the present invention comprises (i) a recombinant nucleotide sequence encoding the F protein or an immunogenic fragment of NDV, preferentially under the control of the Pec promoter, inserted into the intergenic region between HVT065 and HVT066, and (ii) a recombinant nucleotide sequence encoding the gB protein or an immunogenic fragment of ILTV, preferentially under the control of the Pec promoter (FW241), inserted into the intergenic region between HVT053 and HVT054.

[0087] Another recombinant HVT of the present invention comprises (i) a recombinant nucleotide sequence encoding the VP2 protein or an immunogenic fragment of IBDV, preferentially under the control of the Mcmv ie1 promoter or the Pec promoter, inserted into the intergenic region between HVT065 and HVT066, and (ii) a recombinant nucleotide sequence encoding the gB protein or an immunogenic fragment of ILTV, preferentially under the control of the Pec promoter, inserted into the intergenic region between HVT053 and HVT054.

[0088] A further recombinant HVT of the present invention comprises (i) a recombinant nucleotide sequence encoding the gB protein or an immunogenic fragment of ILTV, preferentially under the control of the Mcmv ie1 promoter or the Pec promoter, inserted into the intergenic region between HVT065 and HVT066, and (ii) a recombinant nucleotide sequence encoding the VP2 protein or an immunogenic fragment of IBDV, preferentially under the control of the Pec promoter (FW259), inserted into the intergenic region between HVT053 and HVT054.

[0089] The recombinant HVT of the present invention can be propagated in cell culture. In a preferred embodiment, CEF, embryonated eggs, chicken kidney cells, etc. are used as host cells for the propagation of the recombinant HVT. The polyvalent recombinant HVT of the present invention can be cultured in a medium such as Eagle's minimum essential medium, Leibowitz-L-15 / McCoy 5A (1:1 mixture) medium, etc. at about 37°C for 3 to 4 days. The infected cells thus obtained are suspended in a medium containing 10% dimethyl sulfoxide (DMSO) and frozen and stored under liquid nitrogen.

[0090] Advantageously, the recombinant multivalent HVT of the present invention exhibits a high level of stability throughout the passages, even after 10 or more passages, preferably after 15 passages, and even more preferably after 20 passages, corresponding to the simultaneous expression of the recombinant nucleotide sequences in cells of an avian species, preferably CEF cells. In the context of the present invention, "passage" or "cell passaging" means the cultivation of cells in suitable conditions to allow their proliferation and to keep them alive, until the cells are 90% to 100% confluent. The passaging step consists of transferring a small number of cells from a previous confluent culture into a new culture medium. An aliquot of the previous confluent culture containing a small number of cells can be diluted in a large volume of fresh medium.

[0091] The viruses may be harvested or purified using conventional techniques. They may be stored in any suitable medium, frozen and / or lyophilized.

[0092] Nucleic Acids and Cells A further object of the invention relates to any nucleic acid contained in a virus as defined above. The nucleic acid may be single-stranded or double-stranded, DNA or RNA, or a variant thereof.

[0093] The present invention also relates to vectors (eg, plasmids, cosmids, artificial chromosomes, etc.) comprising the nucleic acids of the present invention.

[0094] The present invention also relates to cells containing a recombinant HVT, nucleic acid or vector of the present invention. The cells are generally eukaryotic cells, such as avian cells, or prokaryotic cells (if the vector is suitable for replication or maintenance in such cell types).

[0095] Vaccine Compositions The present invention also relates to compositions, such as vaccines, comprising the multivalent recombinant HVT of the present invention, the nucleic acid of the present invention, or the cell of the present invention.

[0096] The vaccines of the present invention generally comprise an immunologically effective amount of a recombinant HVT, as described above, in a pharma- ceutically acceptable vehicle.

[0097] The compositions and vaccines according to the present invention generally contain suitable solvents or diluents or excipients, such as aqueous buffer or phosphate buffer.The compositions may also contain additives such as proteins or peptides (e.g., hormones, cytokines, costimulatory factors) derived from animals, nucleic acids (e.g., double-stranded RNA, CpG) derived from viruses and other sources, which are administered in sufficient amounts in the vaccine to enhance immune response.In addition, any number of combinations of the aforementioned substances may produce immune-enhancing effects, thus forming the immune-enhancing agent of the present invention.

[0098] The vaccines of the present invention may be further formulated with one or more additional additives to maintain isotonicity, physiological pH and stability, such as saline (0.85%), phosphate buffered saline (PBS), citrate buffer, Tris(hydroxymethylaminomethane (TRIS), Tris-buffered saline, or antibiotics, such as neomycin or streptomycin.

[0099] The route of administration can be any route, including oral, ocular (e.g., by eye drops), oculonasal administration using an aerosol, intranasal, in-feed, in-water, or by spray, in ovo, topical, or by injection (e.g., intravenous, subcutaneous, intramuscular, intraorbital, intraocular, intradermal, and / or intraperitoneal) vaccination. Those skilled in the art will readily adapt the formulation of the vaccine composition for each type of administration route.

[0100] Each vaccine dose may contain an appropriate dose sufficient to induce a protective immune response in the avian species. Optimization of such doses is well known in the art. The amount of antigen per dose may be determined by known methods using antigen / antibody reactions, such as ELISA.

[0101] The vaccines of the present invention can be administered as a single dose or in multiple doses, depending on the vaccination protocol.

[0102] The vaccines of the present invention are further advantageous in that they provide bird species with up to 80% protection against targeted avian pathogens after three weeks of vaccination.

[0103] The present invention further relates to the use of the above vaccines for immunizing avian species, such as poultry, against pathogens.

[0104] The present invention further relates to a method of immunizing an avian species by administering an immunologically effective amount of a vaccine according to the present invention. The vaccine may be advantageously administered intradermally, subcutaneously, intramuscularly, orally, in ovo, mucosally, or by oculonasal administration.

[0105] The present invention further relates to vaccination kits for immunizing avian species comprising an effective amount of the multivalent vaccine described above and means for administering the components to the avian species. For example, such a kit may comprise an injection device filled with the multivalent vaccine according to the invention and instructions for intradermal, subcutaneous, intramuscular, or in ovo injection. Alternatively, the kit may comprise a spray / aerosol or eye drop device filled with the multivalent vaccine according to the invention and instructions for ophthalmological, oral, or mucosal administration.

[0106] Further aspects and advantages of the present application will now be disclosed in the following examples which are illustrative of the invention. EXAMPLES

[0107] In the experimental section, several recombinant HVTs (monovalent or multivalent according to the invention) were generated and named as follows (HVT / first insertion site-first foreign gene / second insertion site-second foreign gene). Single price: FW200:HVT / 65-66 Pec F FW219:HVT / 65-66 Pec gB FW168:HVT / 45-46 Pec F FW169:HVT / 45-46 Bac VP2 FW181:HVT / 45-46 Pec gB Multivalent: FW241:HVT / 65-66 Pec F / 45-46 Pec gB FW242:HVT / 65-66 Pec gB / 45-46 Pec F FW243:HVT / 65-66 Mcmv ie1 F / 45-46 Pec gB FW244:HVT / 65-66 Mcmv ie1 gB / 45-46 Pec F FW259:HVT / 65-66 Pec gB / 45-46 Bac VP2

[0108] Example 1: Construction of a homology vector Plasmid construction was essentially performed by standard molecular biology techniques (Molecular Cloning: A Laboratory Manual. 4th Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 2012). DNA restriction fragments were electrophoresed on an agarose gel and purified with Plasmid plus Midi Kit (QIAGEN, Catalog No. 12945).

[0109] HVT DNA was prepared from CEF cells infected with HVT FC126 strain according to the method of Lee et al. (J. Gen. Virol., 51:245-253, 1980). HVT064-071 was amplified by PCR using the obtained HVT DNA as a template. Two primers were used. One was sequence number 4 (5'-GGATGTCCAATTCGCACATG-3') and the other was sequence number 5 (5-GCTACAGTTACGGGATTCATAGG-3'). Each primer was designed based on the information in GenBank AF291866.1.

[0110] Construction of pHVT64-65 Using HVT064-071 as a template, PCR was performed using two pairs of primers. A DNA fragment with an SfiI site between the two ORFs, HVT064 (LORF3) and HVT065 (UL55), was prepared by PCR and cloned into pUC18.

[0111] The first pair was SEQ ID NO:6 (5'-GGGGGAATTCACTACTTTTAATTCTCTTTA-3') and SEQ ID NO:7 (5'-GGGGGCCAATAAGGCCGCTAGCGGCCGCCTAACACCCCCGAATATTAGTC-3').

[0112] The second pair was SEQ ID NO:8 (5'-GGGGCGGCCGCTAGCGGCCTTATTGGCCTCACGTGTAGCCCATTGTGTGCATATAAC-3') and SEQ ID NO:9 (5'-GGGAAGCTTAGATCTGAAATAACGCAGTTG-3').

[0113] The first fragment obtained was digested with EcoRI and NheI. The second fragment obtained was digested with NheI and HindIII. These cleaved fragments were inserted into pUC18 cleaved with EcoRI and HindIII to obtain plasmid pHVT 64-65.

[0114] Construction of pHVT65-66 Using HVT064-071 as a template, PCR was performed using two pairs of primers. A DNA fragment with an SfiI site between the two ORFs, HVT065 (UL55) and HVT066 (LORF4), was prepared by PCR and cloned into pUC18.

[0115] The first pair was SEQ ID NO:10 (5'-GGGGAATTCGCCAGATATCCAAAGTACAGC-3') and SEQ ID NO:11 (5'-GGGGGCCAATAAGGCCGCTAGCGGCCGCCAATTATTTTATTTAATAACATAT-3').

[0116] The second pair was SEQ ID NO:12 (5'-GGGGCGGCCGCTAGCGGCCTTATTGGCCACCAGTGAACAATTT GTTTAATGTTA-3') and SEQ ID NO:13 (5'-GGGAAGCTTGGGTCTGTCCTAGCGATATAA-3').

[0117] The first fragment obtained was digested with EcoRI and NheI. The second fragment obtained was digested with NheI and HindIII. These cleaved fragments were inserted into pUC18 cleaved with EcoRI and HindIII to obtain plasmid pHVT 65-66.

[0118] Construction of pHVT66-67 Using HVT064-071 as a template, PCR was performed using two pairs of primers. A DNA fragment with an SfiI site between two ORFs, HVT066 (LORF4) and HVT067 (LORF5), was prepared by PCR and cloned into pUC18.

[0119] The first pair was SEQ ID NO:14 (5'-GGGGGAATTCTCCAGATTGTTGGATATCTG-3') and SEQ ID NO:15 (5'-GGGGGCCAATAAGGCCGCTAGCGGCCGCCTTATTGATTTATAAAAACATACATGCAGTG-3').

[0120] The second pair was SEQ ID NO:16 (5'-GGGGCGGCCGCTAGCGGCCTTATTGGCCAGTACATAATTTATTACGTATCATTTCCG-3') and SEQ ID NO:17 (5'-GGGAAGCTTCCTGCAAGACCTCATACGGAA-3').

[0121] The first fragment obtained was digested with EcoRI and NheI. The second fragment obtained was digested with NheI and HindIII. These cleaved fragments were inserted into pUC18 cleaved with EcoRI and HindIII to obtain plasmid pHVT 66-67.

[0122] Construction of pHVT67-69 Using HVT064-071 as a template, PCR was performed using two pairs of primers. A DNA fragment with an SfiI site between two ORFs, HVT067 (LORF5) and HVT069 (LORF6), was prepared by PCR and cloned into pUC18.

[0123] The first pair was SEQ ID NO:18 (5'-GGGGGAATTCATTTCTTCATTGCAACGACG-3') and SEQ ID NO:19 (5'-GGGGGCCAATAAGGCCGCTAGCGGCCGCATGATCGTGCTCATTACTGCATCG-3').

[0124] The second pair was SEQ ID NO:20 (5'-GGGGCGGCCGCTAGCGGCCTTATTGGCCGGGCGGGGCGATGACGTTCTATTTGC-3') and SEQ ID NO:21 (5'-GGGAAGCTTAATACGCAGATTCTTTTCGG-3').

[0125] The first fragment obtained was digested with EcoRI and NheI. The second fragment obtained was digested with NheI and HindIII. These cleaved fragments were inserted into pUC18 cleaved with EcoRI and HindIII to obtain plasmid pHVT 67-69.

[0126] Construction of pHVT69-70 Using HVT064-071 as a template, PCR was performed using two pairs of primers. A DNA fragment with an SfiI site between the two ORFs, HVT069 (LORF6) and HVT070, was prepared by PCR and cloned into pUC18.

[0127] The first pair was SEQ ID NO:22 (5'-GGGGGAATTCTAAAGAATCGTACATGAGCG-3') and SEQ ID NO:23 (5'-GGGGGCCAATAAGGCCGCTAGCGGCCGCCTGATGTATAAGATTGCCGAAAAG-3').

[0128] The second pair was SEQ ID NO:24 (5'-GGGGCGGCCGCTAGCGGCCTTATTGGCCCGGGTTGCGTGAATACTGGTCACAG-3') and SEQ ID NO:25 (5'-GGGAAGCTTACGATCTGGCAAAAGGGTCC-3').

[0129] The first fragment obtained was digested with EcoRI and NheI. The second fragment obtained was digested with NheI and HindIII. These cleaved fragments were inserted into pUC18 cleaved with EcoRI and HindIII to obtain plasmid pHVT 69-70.

[0130] Construction of homology vector, pHVT65-66 Pec F SfiI-cleaved pHVT65-66 was dephosphorylated using alkaline phosphatase Shewanella sp. S1B1 recombinant (PAP) (Funakoshi #DE110). The fragment was ligated with BglI-cleaved p45 / 46Pec F (WO2003 / 001066) to obtain plasmid pHVT65-66 Pec F. A synthetic short polyA signal (SPA: SEQ ID NO: 26 CTGCAGGCGGCCGCTCTAGAGTCGACAATAAAAGATCTTTATTTTCATTAGATCTGTGTGTTGGTTTTTTGTGTGGCCAATAAGGCC) was incorporated into SalI- and SfiI-cleaved pHVT65-66 Pec F to obtain the homology plasmid pHVT65-66 Pec F SPA.

[0131] Construction of the homology vector, pHVT65-66 Pec gB The homology vector, pHVT65-66 Pec F SPA, was cut with XbaI and NotI. The 5210-bp fragment was ligated with XbaI / NotI cut pHVT87-88 Pec ILgB del (WO2013 144355) (1506 bp) to obtain the homology plasmid pHVT65-66 Pec gB SPA.

[0132] Chemically synthesized McMv ie1 promoter The Mcmv ie1 promoter (sequence number 3) was synthesized based on the information of 4191-4731 bp of Gene Bank L06816.1 reported by Koszinowski, UH, and the synthetic Mcmv ie1 promoter was designed to add a BglI-PstI site in front of it and an XbaI-NotI site at the end.

[0133] Example 2: Purification of recombinant HVT in CEFs transfected with each transfer vector Viral DNA of HVT wild-type FC126 strain (wt-HVT) was prepared as described by Morgan et al. (Avian Diseases, 34:345-351, 1990). Viral DNA of FW168 (rHVT / 45-46PecF), FW169 (rHVT / 45-46BacVP2) and FW181 (rHVT / 45-46PecgBdel) (WO2005 093070) was prepared in a similar manner. The first double rHVT pattern was transfected with the prepared wt-HVT DNA and pHVT65-66Pec F (e.g. FW200) into CEF cells. The second pattern was transfected with the prepared FW168 DNA and pHVT65-66 Pec gB (e.g. FW242) into CEF cells. The third pattern was transfecting CEF cells with prepared FW181 DNA and pHVT65-66 Pec F (e.g., FW241). The fourth pattern was transfecting CEF cells with prepared FW169 DNA and pHVT65-66 Pec gB (e.g., FW259). The resulting recombinant viruses were plaque-purified by staining the plaques with anti-ILTV gB, anti-NDV-F, or anti-IBDV-VP2 antibodies.

[0134] In short, 10 7Suspend primary CEF cells in 100 μL of MEF-1 (Lonza LNJVD-1004) and co-transfect with 1 μg of homology vector (e.g., pHVT65-66 PecF, pHVT65-66 Mcmv ie1 gB) and 2 μg of HVT DNA (e.g., FC126, FW181, FW168) by electroporation. Electroporation was performed with a Nucleofector II. Dilute the transfected cells into 20 mL of Leibovitz's L-15 (GIBCO BRL, Cat. #41300-39), McCoy's 5A medium (GIBCO BRL, Cat. #21500-061) (1:1), and 4% calf serum (named solution LM(+) medium) and distribute 100 uL per well into a 96-well plate.

[0135] The plates were incubated at 37°C with 5% CO2 until plaques were visible, and the cells were detached from the plates by trypsinization, diluted with freshly prepared secondary CEF cells, and evenly transferred to two 96-well plates and incubated for 3 days to visualize the plaques. One of the two plates was then stained with antibodies to detect the inserted genes carried by each transfer vector as the primary antibody. NDV-F was detected by anti-Fc rabbit serum or Mab77-2. ILTV-gB was detected by anti-ILTV gBN4 rabbit serum or Mab#1_B4_7. IBDV-VP2 was detected by anti-VP2 monoclonal antibody R63 (ATCC number: HB-9490). After detecting wells containing stained recombinant plaques, cells were collected from the corresponding wells of the other plate, diluted with new secondary CEF cells, and evenly transferred to two 96-well plates to complete the first round of purification. The purification procedure was repeated until all the obtained plaques were positively stained with each polyclonal or monoclonal antibody. Then, the double rHVT candidates were stained with another antibody. Finally, the expression of proteins by all the plaques of the candidate rHVTs was confirmed by double IFA staining. CEFs infected with each rHVT were fixed with cold acetone-methanol (2:1), washed with PBS, and reacted with antibody mixture (anti-gBN4 rabbit serum (or Mab#1_B4_1) and anti-Fc rabbit serum (Mab77-2) or anti-VP2 mouse Mab R63 at 1:1000 dilution) at 37C for 60 min. After washing three times with PBS, the cells were reacted with fluorescent antibody mixture (Alexa Fluor 488 anti-rabbit and Alexa Fluor 546 anti-mouse provided by Invitrogen at 1:1000 dilution) at 37C for 60 min. After washing three times with PBS, the cells were observed under a fluorescent microscope at 40x or 100x magnification.

[0136] The expression of protein gB was detected by anti-gBN4 rabbit serum and Alexa Flour 546. The expression of protein F was detected by anti-F Mab 77-2 and Alexa Flour 488. The expression of protein VP2 was detected by anti-VP2 Mab (R63) and Alexa Flour 546. The purification was concluded to be complete when all plaques expressed both F and gB (both gB and VP2). Figures 2A and B show some examples of dual IFA.

[0137] The purified recombinant HVT was designated rHVT / ND / ILT or rHVT / ILT / IBDV.

[0138] Table 1 below shows the expression of gB and protein F obtained from various rHVT / ND / ILTs.

[0139] Strains FW168 (HVT / 45-46 PecF) and FW200 (HVT / 65-66 PecF) correspond to monovalent recombinant herpesviruses used as controls for protein F expression, FW181 (HVT / 45-46 Pec gBdel) and FW219 (HVT / 65-66 Pec gBdel) correspond to monovalent recombinant herpesviruses used as controls for protein gB expression, and FW169 (HVT / 45-46 Bac VP2) corresponds to monovalent recombinant herpesviruses used as controls for VP2 expression.

[0140] The results demonstrate that the bivalent construct of the invention expresses both antigens.

[0141] [Table 1]

[0142] Example 3: Simultaneous expression of two proteins in CEF infected with double recombinant HVT 2×10 5 CEF cells were infected with recombinant HVT and incubated at 37° C. in 5% CO 2 for 3 days.

[0143] The culture was then centrifuged at 300g for 3 min, and the precipitated cells were resuspended in 100uL. Laemmli buffer (100uL) was added to the cell suspension. The resulting mixture was then boiled for 5 min, and 5ul of them were subjected to 10% SDS-polyacrylamide gel electrophoresis. The electrophoresed proteins were transferred from the SDS-GEL to a PVDF membrane (Immobilon-P, Millipore) and blocked in 1% w / v nonfat dry milk in PBS for 1 h at room temperature.

[0144] Then, for F detection (Fig. 3A ), the treated membrane was reacted with 500-fold diluted anti-Fc rabbit antiserum for 1 h at room temperature, washed three times with PBS, and incubated with biotinylated anti-rabbit goat antiserum for 1 h.

[0145] For gB detection (Fig. 3B ), the treated membranes were reacted with 1:500 diluted anti-gBN4 rabbit serum for 1 h at room temperature, washed three times with PBS, and incubated with biotinylated anti-rabbit goat antiserum for 1 h.

[0146] After washing three times with PBS, the membrane was incubated with avidin-alkaline phosphatase complex for 1 h, washed three times with PBS and once with TBS (Tris-buffered saline), and then reacted with BCIP-NBT (a substrate for alkaline phosphatase). As shown in Figure 3A, a 60 kilodalton (kDa) protein band was observed only in the lane of rHVT / ND / ILT-infected cells, which is the expected size of the F protein ( ). There was no band in the lane of rHVT / 45-46 Pec gB(FW181).

[0147] Figure 3B shows that in each rHVT / ND / ILT lane, gB protein was observed at 54 kilodaltons (kd).

number

[0148] The double recombinant HVT according to the present invention expressed both NDV-F and ILTV-gB.

[0149] Example 4: Verification of genome structure PCR analysis Purified rHVT / ND / ILT were propagated on CEF cells in one 6-well plate to obtain confluent plaques. Cells were harvested from the dish by scraping, transferred to a Falcon tube, and centrifuged at 300xg for 5 min. One-tenth of the harvested cells (from one well) were suspended in 0.1 mL of lysis buffer (20 mM Tris-HCl, 100 mM NaCl, 5 mM EDTA, 0.1% SDS) and lysed by vortexing for 1 min. The lysate was incubated with 2 μL of Protease K (10 mg / mL) at 60 °C for 10 min. The resulting mixture was treated twice with phenol-chloroform. The aqueous phase (viral DNA) was used as template.

[0150] Primer sets were designed for each insertion site.

[0151] For analysis around HVT65 / 66 65R (SEQ ID NO: 27): 5'-CCACTGCCACTGTGATGATAAG-3' 66F (SEQ ID NO: 28): 5'-GCCTACTATGCACATTGTTACTCCT-3' For analysis around UL45 / 46 45-46F-K (SEQ ID NO: 29): 5'-GGGGAAGTCTTCCGGTTAAGGGAC-3' 45-46R (SEQ ID NO: 30): 5'-GGTGCAATTCGTAAGACCGATGGG-3' PCR was performed using Tks Gflex DNA polymerase (TAKARA BIO Inc. #R060) according to the manufacturer's manual.

[0152] The PCR results in Fig. 4C show that a 2550-bp fragment was amplified with the primer set 66F / 65R with purified DNA from FW243(p+1). The fragment amplified in transfer plasmid pHVT65-66 ie1 NDV-F was of the same size. In addition, a 2281-bp fragment was amplified with another primer set 45-46-K / 45-46R with purified DNA from FW243(p+1) (Fig. 4D). The same band was detected in p45-46 Pec gBdel. The lower fragment (546 bp) was amplified with pNZ45-46 Sfi-T.

[0153] Figure 4C-D (p+1) shows that the obtained double recombinant HVT / ND / ILT has the expected genome structure. The recombinant virus was confirmed to be pure because no band corresponding to the parent strain was amplified.

[0154] Example 5: Stability of recombinant HVT during passage PCR analysis Each rHVT / ND / ILT was passaged 20 times in CEF cells and PCR analysis was performed as described in Experiment 4. The results were the same as those obtained in Experiment 4, indicating that the recombinant virus was stable after 20 passages.

[0155] The PCR results in Figure 4A show that a 2118-bp fragment was amplified with primer set 66F / 65R in DNA from FW242 (p+5, +10, +15, +20) and transfer plasmid pHVT65-66 Pec gBdel. In contrast, the lower fragment (252 bp) was amplified in the unpurified clone.

[0156] Figure 4B shows that a 3083-bp fragment was amplified using another primer set 45-46-K / 45-46R in FW242 (p+5, +10, +15, +20) and p45-46 Pec F 2nd. The lower band (547 bp) was amplified in pNZ45-46 Sfi-T (US 7569365).

[0157] Figure 4C shows that a 2550-bp fragment was amplified in passaged FW243 (p+5, +10, +15, +20), and Figure 4D shows that a 2281-bp fragment was amplified in passaged FW243 (p+5, +10, +15, +20).

[0158] PCR analysis with 65R / 66F and 45-46-K / 45-46R showed that the F or gB gene was stably maintained at the insertion site HVT65 / 66 or UL45 / 46 in FW242 and FW243, respectively.

[0159] Western blotting analysis The double recombinant HVT was serially passaged (up to 20 times) on chicken embryo fibroblasts (CEF). The cell lysates were then applied to Western blot analysis. In the first panel (FIG. 5A), the blot was reacted with anti-Fc rabbit serum (1:500). In the second panel (FIG. 5B), the blot was reacted with anti-gBN4 rabbit serum (1:500).

[0160] False: Uninfected CEF M:Precision Plus Protein Standards Bio Rad#161-0374 After 20 passages, NDV-F protein

number

number

[0161] Example 6: Induction of anti-NDV antibodies in chickens inoculated with double recombinant HVT Ten one-day-old SPF chickens (Line M, NISSEIKEN) were subcutaneously inoculated with the double recombinant HVT on the back using a 20-gauge syringe. The inoculation dose is shown in Table 2. Serum was collected from the vaccinated chickens and anti-NDV antibody titers were measured by a commercially available ELISA kit (IDVET, ID Screen Newcastle Disease Indirect Kit for diagnosing Newcastle disease). Chickens in the negative control group (non-immunized) were not administered the vaccine.

[0162] Table 2 shows the anti-NDV titers according to the S / P values. The results clearly show that the double recombinant HVT according to the present invention induced anti-NDV antibodies as early as 3 weeks after inoculation, and then increased anti-NDV antibodies.

[0163] [Table 2]

[0164] Example 7: Efficacy of rHVT / ND / ILT in SPF chickens against ILTV The efficacy of rHVT / ND / ILT (FW241, FW242, FW243, and FW244) as an ILT vaccine was evaluated by challenge with the ILTV USDA strain.

[0165] The double recombinant HVT was inoculated subcutaneously into the back of 1-day-old SPF chickens. Four weeks after inoculation, the vaccinated chickens were intratracheally (IT) injected with 100 μg of the ILTV USDA strain. 3 EID 50 100 / bird was challenged. The challenged chickens were observed daily to count mortality and to detect symptoms of infectious laryngotracheitis, such as prostration, labored breathing, rales, bloody sputum, sneezing, gasping, head shaking, neck stretching, or ruffling of feathers. The results 10 days after challenge are summarized in Table 3.

[0166] [Table 3]

[0167] As shown in Table 3, all of the double recombinant HVTs according to the present invention induced protective immunity against challenge with virulent ILTV in chickens.

[0168] Example 8: Efficacy of rHVT / ND / ILT against NDV in SPF chickens The efficacy of rHVT / ND / ILT (FW241, FW242, FW243, and FW244) as ND vaccines was evaluated.

[0169] 2,000 PFU / 200 μL / chicken of rHVT / ND / ILT was subcutaneously inoculated into the backs of 15 1-day-old SPF chickens (LineM, Japan Biological Laboratories) using a 20-gauge syringe. From 3 weeks after vaccination, serum was collected from the vaccinated birds and anti-NDV antibody titers were measured using a commercially available ELISA kit (IDVET, ID Screen Newcastle Disease Indirect Kit for diagnosing Newcastle disease).

[0170] The negative control group of chickens did not receive the vaccine (NI: non-immunized).

[0171] At 49 days of age (48 days post-vaccination), chickens in all five groups were vaccinated with 10% NDV-TexasGB, a strain frequently used as a challenge strain in efficacy studies. 3 EID 50 The chickens were challenged with 100% sera from the chickens by intramuscular injection into the thigh. The challenged chickens were observed daily to count mortality and detect any symptoms of Newcastle disease, such as weakness, gasping, neurological symptoms, moribundity, etc. The results 10 days after challenge are shown in Table 4.

[0172] [Table 4]

[0173] As shown in Table 4, all of the double recombinant HVTs according to the present invention induced protective immunity in chickens against challenge with NDV.

Claims

1. 1. A recombinant herpesvirus of turkeys ("HVT") comprising at least a first and a second recombinant nucleotide sequence, each recombinant nucleotide sequence encoding a polypeptide, wherein the first recombinant nucleotide sequence is inserted into an intergenic region of the viral genome located between HVT053 and HVT054, and the second recombinant nucleotide sequence is inserted into an intergenic region of the viral genome located between HVT065 and HVT066.

2. 2. The recombinant HVT of claim 1, wherein each recombinant nucleotide sequence encodes an antigen or immunogenic fragment thereof from an avian pathogen.

3. 3. The recombinant HVT of claim 2, wherein each antigen is selected from a surface protein, a secreted protein and a structural protein of said avian pathogen or an immunogenic fragment thereof.

4. 4. The recombinant HVT according to claim 2 or 3, wherein each recombinant nucleotide sequence encodes an antigen selected from among an antigen of avian paramyxovirus type 1, preferably the F protein of Newcastle disease virus (NDV) or an immunogenic fragment thereof, an antigen of Gumboro disease virus, preferably the VP2 protein of infectious bursal disease virus (IBDV) or an immunogenic fragment thereof, an antigen of infectious laryngotracheitis virus (ILTV), preferably the gB protein or an immunogenic fragment thereof, an antigen of Mycoplasma gallisepticum, preferably the 40K protein or an immunogenic fragment thereof, and an antigen of avian influenza virus, preferentially the surface protein hemagglutinin (HA) or an immunogenic fragment thereof.

5. The recombinant HVT of any one of claims 1 to 4, wherein the first and second recombinant nucleotide sequences encode different antigens, or immunogenic fragments thereof, from the same or different pathogens.

6. The recombinant HVT of any one of claims 1 to 5, wherein each recombinant nucleotide sequence is under the control of a promoter.

7. The recombinant HVT of claim 6, wherein each promoter controlling the expression of the recombinant nucleotide sequence is selected from the chicken beta actin (Bac) promoter, the Pec promoter, the mouse cytomegalovirus (Mcmv) immediate early (ie)1 promoter, the human cytomegalovirus promoter (Hcmv), the simian virus (SV) 40 promoter, and the Rous sarcoma virus (RSV) promoter, or any fragment thereof that retains promoter activity.

8. 8. The recombinant HVT according to any one of claims 1 to 7, comprising: (i) a recombinant nucleotide sequence encoding the F protein or an immunogenic fragment thereof of NDV, preferentially under the control of the Mcmv ie1 promoter, inserted in the intergenic region between HVT065 and HVT066; and (ii) a recombinant nucleotide sequence encoding the gB protein or an immunogenic fragment thereof of ILTV, preferentially under the control of the Pec promoter, inserted in the intergenic region between HVT053 and HVT054.

9. 8. The recombinant HVT according to any one of claims 1 to 7, comprising: (i) a recombinant nucleotide sequence encoding the F protein or an immunogenic fragment thereof of NDV, preferentially under the control of the Mcmv ie1 promoter, inserted in the intergenic region between HVT065 and HVT066; and (ii) a recombinant nucleotide sequence encoding the gB protein or an immunogenic fragment thereof of ILTV, preferentially under the control of the Pec promoter, inserted in the intergenic region between HVT053 and HVT054.

10. 8. The recombinant HVT according to any one of claims 1 to 7, comprising: (i) a recombinant nucleotide sequence encoding an F protein or an immunogenic fragment thereof of NDV, preferentially under the control of the Pec promoter, inserted in the intergenic region between HVT065 and HVT066; and (ii) a recombinant nucleotide sequence encoding a gB protein or an immunogenic fragment thereof of ILTV, preferentially under the control of the Pec promoter, inserted in the intergenic region between HVT053 and HVT054.

11. 8. The recombinant HVT according to any one of claims 1 to 7, comprising: (i) a recombinant nucleotide sequence encoding an ILTV gB protein or an immunogenic fragment thereof, preferentially under the control of the Mcmv ie1 promoter, inserted in the intergenic region between HVT065 and HVT066; and (ii) a recombinant nucleotide sequence encoding an NDV F protein or an immunogenic fragment thereof, preferentially under the control of the Pec promoter, inserted in the intergenic region between HVT053 and HVT054.

12. A nucleic acid comprising the genome of a recombinant HVT according to any one of claims 1 to 11.

13. A cell comprising a recombinant HVT according to any one of claims 1 to 11, or a nucleic acid according to claim 12.

14. A composition comprising a recombinant HVT according to any one of claims 1 to 11 and a suitable excipient or diluent.

15. A composition comprising a nucleic acid according to claim 12 or a cell according to claim 13 and a suitable excipient or diluent.

16. A multivalent vaccine comprising an effective immunizing amount of a recombinant HVT according to any one of claims 1 to 11, a nucleic acid according to claim 12 and / or a cell according to claim 13.

17. A recombinant HVT according to any one of claims 1 to 11 for use in immunising birds, such as poultry, against a pathogen.

18. 17. The multivalent vaccine of claim 16 for use in a method for vaccinating birds against at least two pathogens simultaneously.

19. 1. A vaccination kit for immunizing birds, comprising the following components: c. an effective amount of the multivalent vaccine of claim 16, and d. A vaccination kit comprising a means for administering said vaccine to said bird.

Citation Information

Patent Citations

  • Construction and application of recombinant herpesvirus of turkey for expressing GB gene of serum I type Marek's disease virus

    CN106701693A

  • Polyvalent recombinant avian herpesvirus and vaccine for immunizing birds

    JP2015512633A

  • Recombinant vectors expressing antigens of avian influenza virus and uses thereof

    US20180110852A1